Overview
flowchart TD
clinical_trials_choline_2_done["NCT04661280: CHOLINE-2 Study - Donepezil vs Non-"]
style clinical_trials_choline_2_done fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_chol_0["Trial Details"]
clinical_trials_choline_2_done -->|"includes"| clinical_trials_chol_0
style clinical_trials_chol_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_chol_1["Background: Cholinergic Hypothesis in Alzheimer"]
clinical_trials_choline_2_done -->|"includes"| clinical_trials_chol_1
style clinical_trials_chol_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_chol_2["Historical Foundation"]
clinical_trials_choline_2_done -->|"includes"| clinical_trials_chol_2
style clinical_trials_chol_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_chol_3["Donepezil: Mechanism of Action"]
clinical_trials_choline_2_done -->|"includes"| clinical_trials_chol_3
style clinical_trials_chol_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_chol_4["Non-Pharmacological Approaches"]
clinical_trials_choline_2_done -->|"includes"| clinical_trials_chol_4
style clinical_trials_chol_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_chol_5["Cognitive Interventions"]
clinical_trials_choline_2_done -->|"includes"| clinical_trials_chol_5
style clinical_trials_chol_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
The CHOLINE-2 Study is a Phase 3 clinical trial comparing the effectiveness of donepezil versus non-drug approaches in the treatment of newly diagnosed [Alzheimer's disease](/diseases/alzheimers-disease). This comparative effectiveness trial addresses an important clinical question: whether pharmacological treatment with acetylcholinesterase inhibitors provides superior benefit compared to non-pharmacological interventions alone in early-stage AD["@courtin2023"].
Trial Details | Attribute | Value |NCT ID | NCT04661280 |Phase | Phase 3 |Status | Recruiting |Intervention | Donepezil vs Non-drug Approach |Condition | Newly Diagnosed Alzheimer's Disease |Participants | 240 |Sponsor | Assistance Publique - Hôpitaux de Paris |Study Design | Randomized, open-label, parallel-group |
Background: Cholinergic Hypothesis in Alzheimer's Disease
Historical Foundation The cholinergic hypothesis of Alzheimer's disease was first proposed in the 1970s and remains a foundational concept in AD therapeutics[@graves1991]. The hypothesis posits that degeneration of cholinergic neurons in the basal forebrain and their projections to the cortex and hippocampus contributes significantly to the cognitive deficits characteristic of AD.
Key Evidence Supporting the Cholinergic Hypothesis :
Neuropathological findings : Post-mortem studies demonstrate significant loss of cholinergic neurons in the nucleus basalis of Meynert in AD patientsNeurochemical deficits : Marked reduction in acetylcholine and choline acetyltransferase activity in AD brain tissueCorrelation with cognition : Cholinergic marker levels correlate with cognitive test scoresTherapeutic validation : Cholinesterase inhibitors provide modest cognitive benefits, supporting the hypothesis
Donepezil: Mechanism of Action Donepezil is a reversible acetylcholinesterase inhibitor that works by:
Enzyme inhibition : Blocks the breakdown of acetylcholine in the synaptic cleftIncreased acetylcholine : Elevates extracellular acetylcholine levelsEnhanced cholinergic transmission : Improves signaling through nicotinic and muscarinic receptorsPharmacological Properties :
Oral administration (5mg or 10mg daily)
Long half-life allowing once-daily dosing
Selective for acetylcholinesterase over butyrylcholinesterase
Minimal hepatic metabolism with low drug interaction potential[@rogers1996]
Non-Pharmacological Approaches
Cognitive Interventions Cognitive Training :
Structured exercises targeting memory, attention, and executive function
Computer-based and therapist-guided programs
Evidence for improvement in specific cognitive domains
Cognitive Stimulation :
Group-based activities designed to improve social engagement and cognition
Reality orientation, validation therapy techniques
Benefits for mood and behavioral symptoms
Lifestyle Modifications Physical Activity :
Regular aerobic exercise improves cerebral blood flow
May reduce amyloid burden and tau pathology
Associated with better cognitive outcomes in epidemiological studies
Dietary Interventions :
Mediterranean diet adherence correlates with reduced AD risk
Specific nutrients (omega-3 fatty acids, vitamins) may provide neuroprotection
Behavioral Interventions Caregiver Education and Support :
Training in communication strategies
Behavioral management techniques
Stress reduction for caregivers
Environmental Modifications :
Home safety modifications
Routine establishment
Assistive devices for daily activities
Trial Design and Rationale
Study Objectives The CHOLINE-2 trial seeks to answer critical questions about AD treatment:
Primary Objectives :
Compare cognitive outcomes between donepezil and non-drug approaches
Assess functional and behavioral outcomes
Evaluate quality of life measures Secondary Objectives :
Cost-effectiveness analysis
Caregiver burden assessment
Long-term follow-up outcomes
Population Inclusion Criteria :
Newly diagnosed AD (within 12 months of diagnosis)
MMSE score 20-26 (mild disease)[@folstein1975]
Age 65-85 years
Stable concomitant medications
Available caregiver/informant
Exclusion Criteria :
Previous cholinesterase inhibitor use
Significant psychiatric comorbidity
Uncontrolled medical conditions
Treatment Arms | Arm | Description | Duration |
Clinical Evidence: Cholinesterase Inhibitors
Efficacy Data Multiple randomized controlled trials have demonstrated the benefits of donepezil[@birks2006]:
Cognitive Outcomes :
2-3 point improvement on MMSE versus placebo
Benefits observed within 3-6 weeks of treatment
Continued benefit over 12-24 months of treatment
Functional Outcomes :
Slowed decline in activities of daily living
Delayed time to nursing home placement in some studies
Reduced caregiver burden
Behavioral Outcomes :
Reduction in apathy and agitation
Improvement in neuropsychiatric symptoms
Limitations Despite widespread use, cholinesterase inhibitors have limitations[@cummings2020]:
Modest effect size : Clinical significance variableSymptomatic only : No disease-modifying effectResponse variability : Not all patients benefitSide effects : Gastrointestinal symptoms, insomniaNon-Pharmacological Evidence
Cognitive Interventions Systematic reviews support the use of cognitive interventions:
Cognitive Training :
Moderate evidence for improvement in specific domains
Transfer to daily activities in some studies
Cognitive Stimulation :
Small but significant benefits for cognition
Additional benefits for mood and quality of life
Lifestyle Interventions Exercise :
Strong evidence for cognitive benefit
Dose-response relationship with exercise intensity
Multicomponent Interventions :
Combined diet, exercise, cognitive training show promise
FINGER trial demonstrated feasibility and benefit
Comparative Effectiveness Considerations
Advantages of Donepezil
Established efficacy from multiple RCTs
Widely available and approved
Well-characterized safety profile
Objective mechanism of action
Advantages of Non-Drug Approaches
No pharmacological side effects
Addresses multiple domains
Can be combined with medications
Patient empowerment and engagement
Lower cost in some healthcare systems
Clinical Implications The CHOLINE-2 trial will provide valuable data for:
Treatment guidelines : Evidence-based recommendationsShared decision-making : Patient preferencesResource allocation : Healthcare planningCombination approaches : Future trial design
Outcome Measures
Primary Endpoints | Measure | Description |
Secondary Endpoints
Quality of life (QoL-AD)
Caregiver burden (Zarit Burden Interview)
Cost-effectiveness measures
Biomarker substudies
Safety and Tolerability
Donepezil Side Effects | Adverse Event | Frequency |
Non-Drug Approach Considerations
Minimal physical risks
Psychological considerations
Accessibility of interventions
Future Implications
Potential Outcomes
Donepezil superiority : Supports early pharmacological interventionNon-drug superiority : Emphasizes lifestyle interventionsComparable outcomes : Suggests combination approachesSubgroup effects : Personalized treatment recommendations
Integration with Future Therapies As disease-modifying therapies become available (anti-amyloid, anti-tau antibodies), the role of symptomatic treatments will evolve. Combination approaches may become standard of care.
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Donepezil](/therapeutics/donepezil)
[Cholinesterase Inhibitors](/entities/cholinesterase-inhibitors)
[Non-pharmacological Alzheimer's Treatments](/therapeutics)
[Clinical Trials Dashboard](/clinical-trials/overview)
External Links
[ClinicalTrials.gov - NCT04661280](https://clinicaltrials.gov/study/NCT04661280)
[Assistance Publique - Hôpitaux de Paris](https://aphp.fr/)
References
[Clinical trial description from task](https://clinicaltrials.gov/study/NCT04661280)
[Courtin et al., Cholinesterase inhibitors in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Folstein et al., Mini-mental state examination (1975)](https://pubmed.ncbi.nlm.nih.gov/1202204/)
[Birks et al., Donepezil for dementia due to Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16494138/)
[Graves, Alzheimer's disease (1991)](https://pubmed.ncbi.nlm.nih.gov/1671234/)
[Cummings et al., Alzheimer's disease drug development pipeline 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32255587/)
[Scheltens et al., Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33756069/)
[Winblad et al., Donepezil in severe Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16464132/)
[Rogers et al., A 24-week open-label trial of donepezil (1996)](https://pubmed.ncbi.nlm.nih.gov/8691339/) Show full description